NEOG vs QDEL
Neogen Corp. and QuidelOrtho Corp., side by side — 6 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NEOG | QDEL |
|---|---|---|
| Revenue | $870.4M | $2.7B |
| Net income | $-7.9M | $-1.1B |
| Gross margin | 46.9% | 46.7% |
| Net margin | −0.9% | −41.5% |
| Return on equity | −0.4% | −46.1% |
| Diluted EPS | −$0.04 | −$16.69 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $31.9M | $-83.0M |
| Equity | $2.1B | $1.9B |
| Net debt / equity | 0.29× | 1.41× |
| Current ratio | 3.82× | 1.50× |
| Revenue CAGR 5y | 13.2% | 10.4% |
| Profit CAGR 5y | — | — |
QDEL bills 3.1× the revenue of NEOG, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
6 years side by side
| Fiscal year | NEOG | QDEL |
|---|---|---|
| FY2025 | $870.4M | $2.7B |
| FY2024 | $894.7M | $2.8B |
| FY2023 | $924.2M | $3.0B |
| FY2022 | $822.4M | $3.3B |
| FY2021 | $527.2M | $1.7B |
| FY2020 | $468.5M | $1.7B |
Net income by year
Bottom line
| Fiscal year | NEOG | QDEL |
|---|---|---|
| FY2025 | $-7.9M | $-1.1B |
| FY2024 | $-1.1B | $-2.1B |
| FY2023 | $-9.4M | $-10.1M |
| FY2022 | $-22.9M | $548.7M |
| FY2021 | $48.3M | $704.2M |
| FY2020 | $60.9M | $810.3M |
More in this industry